This work has been retracted.
Retracted: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection
Year: 2021
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: Ivermectin is an antiparasitic drug being investigated for repurposing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Ivermectin showed in vitro activity against SARS-COV-2, but only at high concentrations. This meta-analysis investigated ivermectin in 23 randomized clinical trials (3349 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv, and trial registries. The primary meta-analysis was carried out by excluding studies at a high risk of bias. Ivermectin did not show a statistically significant effect on survival (risk ratio [RR], 0.90; 95% CI, 0.57 to 1.42; P = .66) or hospitalizations (RR, 0.63; 95% CI, 0.36 to 1.11; P = .11). Ivermectin displayed a borderline significant effect on duration of hospitalization in comparison with standard of care (mean difference, –1.14 days; 95% CI, –2.27 to –0.00; P = .05). There was no significant effect of ivermectin on time to clinical recovery (mean difference, –0.57 days; 95% CI, –1.31 to 0.17; P = .13) or binary clinical recovery (RR, 1.19; 95% CI, 0.94 to 1.50; P = .15). Currently, the World Health Organization recommends the use of ivermectin only inside clinical trials. A network of large clinical trials is in progress to validate the results seen to date.
Source: Open Forum Infectious Diseases
DOI: 10.1093/ofid/ofab358
Authors: Andrew Hill, Ahmed Abdulamir, Sabeena Ahmed, Asma Asghar, Olufemi Emmanuel Babalola, Rabia Basri, Carlos Chaccour, Aijaz Zeeshan Khan Chachar, Abu Tauib Mohammed Chowdhury, Ahmed Elgazzar, Leah Ellis, Jonathan Falconer, Anna Garratt, Basma Hany, Hashim A Hashim, Wasim Ul Haque, Arshad Hayat, Shuixiang He, Ramin Jamshidian, Wasif Ali Khan, Ravi Kirti, Alejandro Krolewiecki, Carlos Lanusse, Jacob Levi, Reaz Mahmud, Sermand Ahmed Mangat, Kaitlyn McCann, Anant Mohan, Mortezza Shakshi Niaee, Nurullah Okumus, Victoria Pilkington, Chinmay Saha Podder, Ambar Qavi, Houssam Raad, Mohammaed Sadegh Rezai, Surapaneni Sasank, Veerapaneni Spoorthi, Tejas Suri, Junzheng Wang, Hannah Wentzel
Institutions: University of Liverpool, Cardiff and Vale University Health Board, University Hospital of Wales, Nahrain University, University College Hospital, International Centre for Diarrhoeal Disease Research, Combined Military Hospital, Chelsea and Westminster Hospital, Bingham University, Imperial College London, Fatima Memorial Hospital, University of Oxford, Clinica Universidad de Navarra, Barcelona Institute for Global Health, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University, Benha University, Bangladesh Institute of Research and Rehabilitation for Diabetes Endocrine and Metabolic Disorders, Ahvaz Jundishapur University of Medical Sciences, All India Institute of Medical Sciences, Patna, National University of Salta, Universidad de Buenos Aires, University College London, Dhaka Medical College and Hospital, All India Institute of Medical Sciences, Afyonkarahisar Sağlık Bilimleri Üniversitesi, Université de Bordeaux, Biotherapy of Genetic Diseases, Inflammatory Disorders and Cancers, Université Bordeaux Segalen, Mazandaran University of Medical Sciences
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,465
Funder: Rainwater Charitable Foundation
OpenAlex ID: W3121596699
